FDA Scales Back Near-Term Goals For Sentinel Postmarket Data Network
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Janet Woodcock said the agency has not been able to overcome budgetary restrictions that hamper previously discussed plans to develop the Sentinel postmarket drug safety surveillance system into a much broader national resource.
You may also be interested in...
FDA Lands Califf As Top Deputy, Potential Next Commissioner
Renowned cardiologist and clinical trial researcher Robert Califf will join FDA in February as deputy commissioner for medical products and tobacco. Califf is director of Duke University’s Translational Medicine Institute and vice chancellor for Clinical and Translational Research.
FDA Lands Califf As Top Deputy, Potential Next Commissioner
Renowned cardiologist and clinical trial researcher Robert Califf will join FDA in February as deputy commissioner for medical products and tobacco. Califf is director of Duke University’s Translational Medicine Institute and vice chancellor for Clinical and Translational Research.
FDA Lands Duke’s Califf As Top Deputy, Potential Next Commissioner
Renowned cardiologist and clinical trialist Robert Califf will join FDA in February as deputy commissioner for medical products and tobacco.